Corrigendum to: Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity: Protein transfer of tumor antigens onto VLPs (Biotechnology and Bioengineering, (2015), 112, 6, (1102-1110), 10.1002/bit.25537);Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity

Biotechnology and Bioengineering

Volumn 112, Issue 6, 2015, Pages 1102-1110

  Patel, Jaina M ^a   Vartabedian, Vincent F ^a   Kim, Min Chul ^b,c   He, Sara ^a   Kang, Sang Moo ^b   Selvaraj, Periasamy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

Author keywords

Breast cancer; HER 2; Protein transfer; Vaccine; Virus like particles

Indexed keywords

ANTIGENS; CHEMICAL MODIFICATION; DISEASES; MAMMALS; PROTEINS; TUMORS; VACCINES; VIRUSES;

ANTIGEN PRESENTING CELLS; BREAST CANCER; GENETIC MODIFICATIONS; GLYCOSYLPHOSPHATIDYLINOSITOL; HER-2; NATURALLY OCCURRING; PROTEIN TRANSFER; VIRUS-LIKE PARTICLES;

IMMUNE SYSTEM;

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; SUBUNIT VACCINE; CANCER ANTIBODY; DRUG CARRIER; ERBB2 PROTEIN, HUMAN; TUMOR ANTIGEN; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOENGINEERING; CANCER IMMUNIZATION; CANCER SIZE; CELL LYSATE; CELL SURFACE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; INFLUENZA VIRUS; LIPID BILAYER; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PURIFICATION; PROTEIN TRANSPORT; STABLE EXPRESSION; TH1 CELL; TH2 CELL; VIRUS LIKE AGENT; WESTERN BLOTTING; ANIMAL; BLOOD; DISEASE MODEL; GENETICS; HUMAN; IMMUNITY; IMMUNOLOGY; METABOLISM; NEOPLASMS; ORTHOMYXOVIRIDAE;

MUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CANCER VACCINES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; HUMANS; IMMUNITY; MICE; NEOPLASMS; ORTHOMYXOVIRIDAE; RECEPTOR, ERBB-2; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84928436370     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.27185     Document Type: Erratum

References (55)

1. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. 1993. The influence of antigen organization on B cell responsiveness. Science 262(5138):1448-1451.
2. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. 2000. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96(9):3102-3108.
3. Bumgarner GW, Zampell JC, Nagarajan S, Poloso NJ, Dorn AS, D'Souza MJ, Selvaraj P. 2005. Modified cell ELISA to determine the solubilization of cell surface proteins: Applications in GPI-anchored protein purification. J Biochem Biophys Methods 64(2):99-109.
4. Chen Y, Emtage P, Zhu Q, Foley R, Muller W, Hitt M, Gauldie J, Wan Y. 2001. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: Enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther 8(4):316-323.
5. Chen Z, Huang H, Chang T, Carlsen S, Saxena A, Marr R, Xing Z, Xiang J. 2002. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. Cancer Gene Ther 9(9):778-786.
6. Cobern L, Selvaraj P. 1995. An enzymatic method to determine receptor-mediated endocytosis. J Biochem Biophys Methods 30(4):249-255.
7. Cubas R, Zhang S, Kwon S, Sevick-Muraca EM, Li M, Chen C, Yao Q. 2009. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother 32(2):118-128.
8. Cubas R, Zhang S, Li M, Chen C, Yao Q. 2011. Chimeric Trop2 virus-like particles: A potential immunotherapeutic approach against pancreatic cancer. J Immunother 34(3):251-263.
9. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T. Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ. 2007. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67(4):1842-1852.
10. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. 2002. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20(11):2624-2632.
11. Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA. 2004. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 22(10):1916-1925.
12. Galarza JM, Latham T, Cupo A. 2005. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 18(1):244-251.
13. Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Iezzi M, Cavallo F, Musiani P, Forni G, Monaci P. 2005. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 113(1):67-77.
14. Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D. von Hofe E, Ponniah S, Peoples GE. 2008. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 26(20):3426-3433.
15. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. 1998. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188(12):2357-2368.
16. Jennings GT, Bachmann MF. 2008. The coming of age of virus-like particle vaccines. Biol Chem 389(5):521-536.
17. Kang SM, Yoo DG, Lipatov AS, Song JM, Davis CT, Quan FS, Chen LM, Donis RO, Compans RW. 2009. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 4(3):e4667.
18. Kim HJ, Cantor H. 2014. CD4 T-cell subsets and tumor immunity: The helpful and the not-so-helpful. Cancer Immunol Res 2(2):91-98.
19. Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, Huang LQ, Murata S, Sgouros G, Emens LA, Reilly RT, Jaffee EM. 2008. Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest 118(5):1700-1711.
20. Ko EJ, Kwon YM, Lee JS, Hwang HS, Yoo SE, Lee YN, Lee YT, Kim MC, Cho MK, Lee YR, Quan FS, Song JM, Lee S, Moore ML, Kang SM. 2014. Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells. Nanomedicine 11:99-108.
21. Low MG, Saltiel AR. 1988. Structural and functional roles of glycosyl-phosphatidylinositol in membranes. Science 239(4837):268-275.
22. Lua LH, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg AP. 2014. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng 111(3):425-440.
23. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. 2008. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 38(5):1404-1413.
24. McHugh RS, Ahmed SN, Wang YC, Sell KW, Selvaraj P. 1995. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA 92(17):8059-8063.
25. McHugh RS, Nagarajan S, Wang YC, Sell KW, Selvaraj P. 1999. Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Res 59(10):2433-2437.
26. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. 2008. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 57(10):1511-1521.
27. Nagarajan S, Selvaraj P. 2002. Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. Cancer Res 62(10):2869-2874.
28. Nagarajan S, Selvaraj P. 2006. Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: A potential approach for local delivery of cytokines during vaccination. Vaccine 24(13):2264-2274.
29. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, Ohta A. 1999. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190(5):617-627.
30. Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, Ohta A, Koda T, Nishimura S. 2000. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 46 Suppl S52-S61.
31. Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. 2007. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: Results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol 25(24):3680-3687.
32. Peacey M, Wilson S, Baird MA, Ward VK. 2007. Versatile RHDV virus-like particles: Incorporation of antigens by genetic modification and chemical conjugation. Biotechnol Bioeng 98(5):968-977.
33. Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW. 2009. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res 15(18):5937-5944.
34. Piechocki MP, Pilon SA, Kelly C, Wei WZ. 2001a. Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat. Cell Immunol 212(2):138-149.
35. Piechocki MP, Pilon SA, Wei WZ. 2001b. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 167(6):3367-3374.
36. Pilon SA, Piechocki MP, Wei WZ. 2001. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 167(6):3201-3206.
37. Poloso NJ, Nagarajan S, Bumgarner GW, Selvaraj P. 2001. Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules. Vaccine 19(15-16):2029-2038.
38. Poloso NJ, Nagarajan S, Mejia-Oneta JM, Selvaraj P. 2002. GPI-anchoring of GM-CSF results in active membrane-bound and partially shed cytokine. Mol Immunol 38(11):803-816.
39. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. 1997. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15(8):2894-2904.
40. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. 2005. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23(50):5751-5759.
41. Quan FS, Sailaja G, Skountzou I, Huang C, Vzorov A, Compans RW, Kang SM. 2007. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine 25(19):3841-3850.
42. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P, Forni G. 2000. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165(9):5133-5142.
43. Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC. 2004. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res 64(21):8022-8028.
44. Selvaraj P, Dustin ML, Silber R, Low MG, Springer TA. 1987. Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor. J Exp Med 166(4):1011-1025.
45. Shashidharamurthy R, Bozeman EN, Patel J, Kaur R, Meganathan J, Selvaraj P. 2012. Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development. Med Res Rev 32(6):1197-1219.
46. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177-182.
47. Song JM, Hossain J, Yoo DG, Lipatov AS, Davis CT, Quan FS, Chen LM, Hogan RJ, Donis RO, Compans RW, Kang SM. 2010. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 405(1):165-175.
48. Srivatsan S, Patel JM, Bozeman EN, Imasuen IE, He S, Daniels D, Selvaraj P. 2014. Allogeneic tumor cell vaccines: The promise and limitations in clinical trials. Hum Vaccin Immunother 10(1):52-63.
49. Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalianis T, Kiessling R, Ramqvist T. 2005. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 65(13):5953-5957.
50. Thery JC, Spano JP, Azria D, Raymond E, Penault Llorca. 2014. Resistance to human epidermal growth factor receptor type 2-targeted therapies. Eur J Cancer 50(5):892-901.
51. Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B, Heilbrun L, Jones RF. 1999. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 81(5):748-754.
52. Zhang F, Schmidt WG, Hou Y, Williams AF, Jacobson K. 1992. Spontaneous incorporation of the glycosyl-phosphatidylinositol-linked protein Thy-1 into cell membranes. Proc Natl Acad Sci USA 89(12):5231-5235.
53. Zhang R, Li M, Chen C, Yao Q. 2004. SHIV virus-like particles bind and activate human dendritic cells. Vaccine 23(2):139-147.
54. Zhang S, Cubas R, Li M, Chen C, Yao Q. 2009. Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells. Mol Immunol 46(10):1988-2001.
55. Zhang W, Wang L, Liu Y, Chen X, Liu Q, Jia J, Yang T, Qiu S, Ma G. 2014. Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Biomaterials 35(23):6086-6097.